KHPG(SZ:002773)2024-04-24 11:27Financial Performance - The cash inflow from operating activities increased to ¥4,352,805,943.42, up from ¥3,835,123,001.12, representing a growth of approximately 13.5%[6] - The net cash flow from operating activities reached ¥1,218,411,128.75, compared to ¥925,153,384.75 in the previous year, indicating a year-over-year increase of about 31.7%[6] - The total revenue from sales of goods and services was ¥4,271,777,412.23, compared to ¥3,691,535,938.52, marking an increase of approximately 15.7%[6] - The company reported a net profit of CNY 2,226,354,329.15 for the year[18] - The company's operating revenue for 2023 reached ¥3,957,459,641.68, representing a year-over-year increase of 16.77% from ¥3,389,028,158.63 in 2022[104] - Net profit attributable to shareholders for 2023 was ¥1,044,765,761.76, up 16.52% compared to ¥896,670,032.77 in 2022[104] - The net profit after deducting non-recurring gains and losses was ¥1,014,208,451.05, reflecting a 22.85% increase from ¥825,537,109.68 in the previous year[104] Cash Flow - Cash inflow from investment activities totaled ¥4,722,930,488.72, down from ¥5,833,063,790.53, reflecting a decrease of approximately 19%[6] - The net cash flow from investment activities was ¥6,616,219.22, a significant improvement from a negative cash flow of ¥215,552,978.73 in the previous year[6] - Cash inflow from financing activities was ¥9,412,344.00, a decrease from ¥20,695,003.00, representing a decline of about 54.5%[6] - The total cash outflow from operating activities was ¥3,134,394,814.67, compared to ¥2,909,969,616.37, indicating an increase of approximately 7.7%[6] - The cash received from tax refunds was ¥30,519,706.74, down from ¥65,959,584.91, showing a decrease of about 53.8%[6] - The cash paid for taxes was ¥422,039,016.27, slightly up from ¥409,715,735.63, representing an increase of approximately 3%[6] Assets and Equity - The total assets at the end of the period amount to CNY 5,908,418,872.53[18] - The total equity attributable to owners is CNY 5,680,957,236.72[18] - The company's registered and paid-in capital as of December 31, 2023, is CNY 919,463,954.00[22] - The net assets attributable to shareholders reached ¥7,804,029,406.63, up 13.07% from ¥6,901,806,830.70 in 2022[104] Research and Development - The company’s R&D investment amounted to CNY 452.48 million, up 4.02% from CNY 435.01 million in 2022[133] - The R&D investment accounted for 11.43% of operating revenue, down from 12.84% in the previous year[133] - The company continues to focus on expanding its product offerings in key therapeutic areas, including hypertension and diabetes, while investing in new product development[139] - The company is currently in the II phase of clinical trials for KH110-R01, aimed at treating mild to moderate Alzheimer's disease, which is expected to enhance its competitiveness in the neurology treatment field[157] - The company has several products in various stages of clinical trials, including KH801-R01 for tumors, which is in the IND application stage, expected to receive approval in March 2024[180] Governance and Management - The company has not reported any significant changes in the management team during the reporting period[63] - The company held its annual general meeting on May 23, 2023, with a participation rate of 65.95%[57] - The company held its first extraordinary general meeting of 2023 on August 3, 2023, with a participation rate of 69.57%[57] - The company held its second extraordinary general meeting of 2023 on December 22, 2023, with a participation rate of 66.84%[57] - The chairman of the board, Ke Zunhong, has held his position since February 5, 2001, and will serve until August 3, 2026[59] - Director Ke Xiao increased his shareholding by 3,499,998 shares during the reporting period, bringing his total to 80,259,998 shares[59] Market and Product Development - The company is focusing on expanding its market presence and enhancing product development strategies[66] - The company has emphasized its commitment to social responsibility and environmental sustainability in its operations[70] - The company is actively pursuing new product and technology development to stay competitive in the market[66] - The company’s KH631 eye injection project was included in the 2023 National Key R&D Program, which is expected to enhance sales growth and long-term operational development[119] - The company received approval for high-dose KH631 eye injection clinical trials, aimed at treating vision impairment due to diabetic macular edema, which is anticipated to improve patient compliance and reduce medical burdens[120] Financial Compliance and Reporting - The company’s financial statements comply with the accounting standards and accurately reflect its financial position as of December 31, 2023[26] - The financial report has been confirmed as accurate and complete by the company's legal representative and accounting heads[68] - The board of directors has been fully present for the review of the financial report, ensuring governance compliance[68] - The company has no significant discrepancies between financial reports prepared under domestic and international accounting standards[81] Strategic Initiatives - The company has made significant changes to its marketing strategy, leading to the termination of several projects, including the expansion of the traditional Chinese medicine production line and the marketing service network construction project[195] - The company is focusing on the consistency evaluation of generic drugs, which is crucial for compliance with national regulations[195] - The company has identified a significant market risk in the traditional Chinese medicine sector, leading to a strategic shift in project implementation[195] - The company plans to change the use of remaining raised funds totaling 45.2793 million yuan for other urgent investment projects to enhance the efficiency of fund utilization[196]